Agios Mempersembahkan Hasil Positif dari Studi Fase 3 ENERGIZE Mitapivat pada Talasemia Non-Transfusi-Dependen dalam Sesi Pleno di Kongres Hibrida Asosiasi Hematologi Eropa 2024
=0.0002).Mitapivat demonstrated a statistically significant increase in hemoglobin response rate compared to placebo.Mitapivat also showed statistically significant improvements in the key secondary endpoints associated with change from baseline in FACIT-Fatigue Score and hemoglobin concentration.These improvements were observed across all pre-specified subgroups.In the safety population, the most common adverse events (‰¥10%) in the mitapivat arm were … Baca Selengkapnya
